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DC are specialized APC for T-lymphocytes that initiate CD4-and CD8-mediated immune responses. [1] [2] [3] Fuctional DC can be differentiated in vitro from myeloid precursors or peripheral blood monocytes in the presence of GM-CSF and IL-4. [4] [5] [6] Effective protection and therapy has been achieved by adoptive transfer of DC cultures in which tumor antigens have been artificially introduced into their antigen-presenting pathways by a number of procedures. [5] [6] [7] [8] [9] [10] [11] Various groups have shown that ex vivo infection of DC with recombinant adenovirus encoding for tumor rejection antigens is one of the most efficient systems for delivering tumor antigens and other transgenes into DC. 12, 13 Typical DC differentiated in culture with GM-CSF and IL- 4 are not yet fully matured and need further stimulation to upregulate their immunostimulatory and antigen-presenting capabilities, [1] [2] [3] by increasing MHC antigen-presenting molecules, membrane-bound costimulatory molecules, and cytokine secretion. Maturation is triggered by various bacterial products such as LPS and DNA, [14] [15] [16] cytokines such as TNF␣ and IL-1 17 and importantly, by activated T cells through CD40L-CD40 interactions. 18 Among the changes that occur in DC during maturation, the induction of IL-12 synthesis is considered an absolute requirement for the activation of the anti-tumor cellular immune response. 19 Artificial gene transfer of IL-12 into DC or their precursors has been used to enhance their ability to stimulate T cells both in vivo and in vitro. 20, 21 An important limitation in those studies was the low frequency of DC actually transfected with the IL-12 genes. We reasoned that ex vivo infection of DC with defective recombinant adenovirus would overcome such an obstacle by genetically modifying most DC.
Accordingly, we derived DC cultures from lymphocyte-depleted bone marrow cell suspensions by culturing them for 7 days with GM-CSF and IL-4 as described 5, 10 obtaining 70-90% purity according to the combined immunostaining with mAb anti-MHC class II, CD11c, CD80 and CD86 (data not shown). Cells in our cultures of bone marrow-derived DC displayed a relatively immature phenotype which can be driven to full maturation by LPS and CD40 ligation increasing the expression of CD80 and CD86 whereas losing phagocytic activity.
To assess frequency of productive gene transfer into a variety of cell types, we have described a recombinant defective adenovirus encoding for ␤-galactosidase (AdCMVLacZ), 22 that was used to study the infectivity and gene transfer of DC cultures with defective recombinant adenoviruses. We infected the cells with AdCM-VLacZ at different MOIs and studied the percentage of cells showing enzyme expression. As shown in Figure 1a , a significant proportion of DC expressing ␤-galactosidase activity were detected 48 h after infection at MOIs ranging from 10 4 to 10 3 . However very small percentage of ␤-galactosidase + cells were observed at lower MOIs, in contrast to reports in which MOIs of 100 were effective.
11, 12 Repetition of the experiments with independently titrated batches of AdCMVLacZ confirmed our 23 Since sensitivity of the assay to detect ␤-gal activity has been proposed to underestimate the actual number of transfected cells, 24 subtle differences in the detection threshold can explain the quantitative differences among laboratories to estimate the optimal MOI. In this regard, in accordance with our transduction data, recent evidence shows that production of adenovirally transduced IL-2 and IL-6 in DC greatly increases in the MOI range between 10 3 and 10 4 . 25 Consistently we got up to 90-100% transduction with AdCMVLacZ at MOI of 100 in various cell lines (data not shown) indicating that DC are somehow more difficult to infect with recombinant adenovirus. In our hands infection of BM-derived DC at MOI of 3000 routinely gave 60-80% transfection with AdCMVLacZ with less than 10% loss of viability after 48 h in culture. Those were therefore selected as our working conditions of infection. Lipofectamine was not introduced in the protocols to avoid additional complexity but it should be considered an alternative to downsize adenovirus production needs. 23 We had generated a recombinant defective adenovirus encoding both chains of murine IL-12 (p35 and p40) separated by a ribosomal entry site (IRES) under the transcriptional control of the CMV promoter (AdCMVIL-12). 26 Intratumoral injections of AdCMVIL-12 have been shown to induce a powerful, often curative CD8-mediated immune response. 26 As shown in Figure 1b , infection with AdCMVIL-12 modified in vitro cultured DC to express high levels (1362 pg/ml/10 6 DC) of the IL-12 p70 heterodimer as detected in the supernatant of infected DC cultured for 48 h. It was concluded that AdCMVIL-12 could be a good tool to engineer BMderived DC to produce IL-12 in order to enhance their immunostimulatory properties. We asked as to whether IL-12 gene transduction made DC capable of unleashing effective cellular immune responses against tumor antigens when tranferred into the tumor nodules. In this scenario, DC are not artificially loaded ex vivo with tumor antigens and they need to capture and present tumor antigens after being taken up from the neighboring malignant tissue. Experiments were set up in two murine models of colon adenocarcinoma: CT26 (Balb/c origin) and MC38 (C57Bl/6 origin) which grow aggressively and are considered poorly immunogeneic. As summarized in Table 1 , a single injection of 2.5 × 10 5 syngeneic BMderived DC, which had been infected ex vivo with AdCMVIL-12, induced complete regressions in 84% of the CT26-derived subcutaneous nodules and in 50% of the MC38-derived s.c. tumor nodules when treated 7 days after innoculation of the malignant cells (mean diameter of the nodules between 3 and 6 mm). When similarly raised allogeneic, rather than syngeneic DC, also infected with AdCMVIL-12 and secreting comparable quantities of IL-12 were used, no significant antitumor effect was observed, indicating that compatible antigen presentation was required. Intratumoral injection with transformed fibroblasts similarly infected with AdCMVIL-12 did not show antitumor effect neither in a syngeneic (Balb/c) nor allogeneic (C57Bl/6) setting. Therefore properties of DC absent in transformed fibro- Cultured BM-derived DC or fibroblasts were infected with the indicated recombinant adenovirus at a MOI of 3000, 15 h before their intratumoral injection. In vitro infection was carried out for 1 h in serum-free RPMI 1640 at room temperature and followed by a 14-h incubation in RPMI 1640 5% FCS at 37°C. blasts were required for the antitumor effect beyond the mere transduction with IL-12 genes. It has been reported that fibroblasts retrovirally engineered to secrete IL-12 were efficacious upon peritumoral injection in other tumor models, but at doses at least 10 times higher than the ones used in this study. 27 Autologous DC transfected with control AdCMVlacZ, or untransfected, displayed a marginal antitumor effect within the range of doses used in these experiments. In the case of tumor nodules treated with AdCMVIL-12 transduced syngeneic DC, the malignant masses started to regress several days (5 to 10) after the procedure (data not shown), as if the antitumor effector mechanisms required this period of time to generate a curative response.
Because CT26 tumors were successfully treated in most instances by a single dose of 2 × 10 5 IL-12-producing DC, it was not considered an adequate model to optimize the therapeutic regimen although injections of larger doses of 10 6 IL-12-engineered DC seem to achieve better antitumor efficacy according to our preliminary data (I Melero et al, unpublished observations). With MC38, which is only cured in half of the cases, we are currently exploring potential improvements in the overall antitumor effect using higher and/or repeated intratumoral doses of IL-12-transduced BM-derived DC. It is noteworthy that the level of IL-12 secreted seems to play an important role since in the case of a batch of DC secreting 10 times less IL-12 due to a mistake in the MOI of AdCMVIL-12 used for gene transfer only a very marginal antitumor effect was observed (data not shown).
Cellular requirements for the induction of CT26 tumor regression were studied by selective in vivo depletion with specific anti-CD4 and anti-CD8 mAbs (Figure 2 ). Both CD4 + and CD8 + T cells seemed to play a role since only simultaneous depletion completely abrogated the antitumor effect of IL-12-engineered DC injected into the tumor, with eight of eight tumors progressing under these conditions, while only two of eight progressed in the non-depleted control group. Single CD8 depletion partially impaired the antitumor effect (six of eight tumors progressed), whereas CD4 depletion by itself did not impair or even improve the antitumor effect (none of eight tumors progressed). Such results in this tumor model are consistent with observations obtained in studies using immunotherapy with tumor antigen-pulsed on DC, 19 which showed a crucial role for both CD8 and CD4 subsets during induction of immunity and only for CD8 + T cells during the effector phase. In our case CD4 depletion by itself did not affect tumor regressions indicating that IL-12 gene transduction into DC might be partially bypassing the need for CD4 help in CTL generation. Nevertheless the data obtained upon simultaneous CD4 and CD8 depletion may point to a beneficial involvement of CD4 cells in the overall elicited antitumor effect, which could explain the elimination of the observed residual antitumor activity after single CD8 depletion.
Paraffin-embedded CT26 tumor sections obtained on days 4 and 7 after intratumoral injection of IL-12-engineered DC were examined upon staining with hematoxylin and eosin and compared with untreated tumors. Treated tumors show a marked mononuclear infiltrate and abundant areas of intense necrosis. Granulocytes are also seen in much smaller numbers surrounding necrotic areas. Frozen samples of the same tumors were analyzed by immunostaining showing that the majority of tumor infiltrating mononuclear cells were CD8 + CD4 − but a small contribution of CD4 + cells to the infiltrate could be detected (data not shown). These data are in agreement with the in vivo depletion experiments.
Memory in the immune mechanisms was found when mice who had rejected a tumor nodule 10 weeks earlier upon treatment with AdCMVIL-12-infected DC, remained tumor-free after a second lethal challenge in the opposite flank with tumor cells which aggressively progressed in naive, sex-and age-matched mice (Figure 3 ). These data also indicated that the procedure has induced systemic immunity against tumor cells which can be therapeutically useful to prevent the outgrowth of micrometastasis. In this regard, mice who carried s.c. CT26 tumors bilaterally were able to reject both tumor nodules in six of eight cases when only one of the nodules received intratumoral injection of 10 6 IL-12-engineered DC, whereas all tumors progressed bilaterally in a control group (n = 8) identically intratumorally injected in one of the nodules but with non-transduced DC (data not shown).
Figure 2 T-lymphocytes are required for the antitumor effect of intratumoral injections of BM-derived DC infected with
It was observed that intratumoral injection of IL-12-transduced DC induced CTL specific for CT26 without cytolytic activity against P815 and YAC-1 cells (Figure 4 ). In addition, we took advantage of the fact that CT26 expresses a tumor rejection antigen named AH1. 28 This This would be consistent with the fact that BM-derived DC have been shown to acquire tumor antigens upon in vitro coculture with a tumor cell line without further manipulation. 30 In this regard, it is of interest that DC are very efficient at internalizing apoptotic bodies 31, 32 and maybe they take up antigen from compartments of the tumor nodule undergoing programmed cell death. We are in the process of investigating whether pretreatment of the tumor with agents increasing apoptosis enhance antigen transfer and presentation in our model. It is also conceivable that mechanical effects of injection of fluid into the experimental tumor facilitate release and capture of intracellular antigens. However direct demonstration in this system of tumor antigen capture and transport into T cell areas of lymphoid tissue by the injected DC is the aim of our current and future research. It is noteworthy that our defective recombinant adenovirus have 42 YAC-1 and P815 were from ATCC. Peptide synthesis was performed as described. 28, 43 a deletion in the E3 region so infection does not interfere with the MHC class I antigen presenting pathway. 22, 26 If the scenario of local antigen uptake and following migration through lymphatic vessels holds true, IL-12 secreted by DC will be a potent stimulator of Th1 cells and CTL precursors 33, 34 upon arrival in T cell areas of draining lymph nodes. In addition, IL-12 secreted at the tumor site may downregulate angiogenesis 35 or mediate other antitumor effects, although these mechanisms must be secondary under our conditions because neither IL-12-transfected allogeneic DC nor fibroblasts mediate any measurable antitumor effect. More importantly, IL-12 has been shown to act in an autocrine fashion on DC promoting maturation and migration of DC through the activation of NFB transcription factors. 36 In fact, culture of DC with exogenous recombinant IL-12 induces the secretion of endogenous IL-12 conferring DC with the ability to prime CTL responses. 37 According to these reports, part of the IL-12 detected in our transfected DC could result from the activation of endogenous IL-12 genes in a positive autocrine feed-back. In addition, it has also been reported that spleen mononulear cells or purified B cells pulsed with a defined murine tumor antigen can induce protective immunity only if recombinant IL-12 is coinjected into the footpad. 38 Although only protective but not therapeutic immunity is seen in that model, it would be interesting to understand the role of rIL-12 in enhancing the immunostimulatory properties of DC or other APCs. Moreover, our preliminary data suggest that at least part of the effects seen after transduction of DC by AdCMVIL-12 are mediated by IL-12 in an autocrine fashion (Galofre JC et al, manuscript in preparation).
In conclusion, the reported therapeutic effect of intratumoral injections with AdCMVIL-12 infected DC might have clinical application for a number of reasons: (1) it does not require the identification of tumor antigens; (2) it can be done in every patient provided that DC can be cultured from peripheral blood; (3) avoids the toxicity of systemic doses of IL-12, 39 which have been used to enhance immunotherapy with DC. 38 The advantage in our approach is that IL-12 is presumably secreted at the precise site of antigen presentation and lymphocyte activation. Although clinical feasibility of these kinds of procedures awaits further safety experimentation, we have not observed any noticeable side-effect in animals rejecting their tumors. In this regard, the potential appearance of immunity against normal components of the injected tissue should be carefully evaluated. 40 It will also be important to study comparatively the efficacy of this new approach with other means to use DC in tumor immunotherapy in different tumor models, including those which propose the use of DC transfected with other cytokines. 41 
